Simbrinza Approval History
FDA Approved: Yes (First approved April 19, 2013)
Brand name: Simbrinza
Generic name: brimonidine and brinzolamide
Dosage form: Ophthalmic Suspension
Treatment for: Glaucoma
Simbrinza (brimonidine and brinzolamide) is a fixed combination of an alpha 2 adrenergic receptor agonist and a carbonic anhydrase inhibitor indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Development History and FDA Approval Process for Simbrinza
|Apr 22, 2013||Alcon Announces FDA Approval of Simbrinza Suspension, a New Beta Blocker-Free, Fixed-Combination Therapy for Glaucoma Patients|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.